Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$42.1M
-54.9% from 2023
Prescriptions
4,228
$9,967.83 per claim
Patients
719
686 prescribers
Total spending, 2024
$42.1M
$58,614.72 per patient
Medicare prescription drug plans paid $42.1M for Esbriet in 2024, for 4,228 prescriptions and refills to 719 patients (down 54.9% from 2023). The average cost per claim was $9,967.83.
New York had the highest Medicare cost for Esbriet in 2024: $4.1M for 445 claims, followed by California ($3.8M).
Robert J Kaner, pulmonary disease in New York, NY, had the highest Medicare cost for Esbriet in 2024: 44 claims costing $516K.
Esbriet is made by Roche Holding AG (ROG.SW), listed in the Medicare spending data as Genentech, Inc..
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Robert J Kaner New York, NY | Pulmonary Disease | 44 | Under 11 | $516K |
| Alvaro U Aranda- Rodriguez Guaynabo, PR | Pulmonary Disease | 35 | Under 11 | $367K |
| Uma M Mohanasundaram |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 4,075 | 39,625 | 7,505 | $409.9M |
| 2023 | 1,493 | 9,200 | 1,833 | $93.4M |
| 2024 | 686 | 4,228 | 719 | $42.1M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Internal Medicine |
| 30 |
| Under 11 |
| $342K |
| Sandeep Sahay Houston, TX | Pulmonary Disease | 28 | Under 11 | $322K |
| Toby Maher Los Angeles, CA | Pulmonary Disease | 31 | Under 11 | $308K |
| An H Pham Pottstown, PA | Pulmonary Disease | 30 | Under 11 | $301K |
| Manar K Al Shahrouri Green Bay, WI | Pulmonary Disease | 25 | Under 11 | $261K |
| Elliott Bondi Brooklyn, NY | Pulmonary Disease | 25 | Under 11 | $261K |
| Jamey J Ruiz Maumee, OH | Pulmonary Disease | 18 | Under 11 | $261K |
| Julie A Gebhardt Schaumburg, IL | Nurse Practitioner | 24 | Under 11 | $260K |
| Brian M Morrissey Sacramento, CA | Internal Medicine | 25 | Under 11 | $259K |
| Gregory P Lemense Bozeman, MT | Pulmonary Disease | 25 | Under 11 | $256K |
| Robert C Hyzy Ann Arbor, MI | Pulmonary Disease | 24 | Under 11 | $246K |
| Mary Strek Chicago, IL | Pulmonary Disease | 21 | Under 11 | $232K |
| Peter G Hamm Chevy Chase, MD | Pulmonary Disease | 18 | Under 11 | $230K |
| Erica D Farrand New York, NY | Pulmonary Disease | 23 | Under 11 | $216K |
| Tina M Parmenter Rochester, NY | Nurse Practitioner | 22 | Under 11 | $215K |
| Randall C Bell San Antonio, TX | Pulmonary Disease | 21 | Under 11 | $213K |
| Jad Kebbe Oklahoma City, OK | Pulmonary Disease | 20 | Under 11 | $202K |
| Joseph A Ball Gaithersburg, MD | Pulmonary Disease | 19 | Under 11 | $192K |
| Joseph A Boscia III Spartanburg, SC | Pulmonary Disease | 18 | Under 11 | $181K |
| Enrique Calvo Ayala Royal Oak, MI | Critical Care (Intensivists) | 24 | Under 11 | $171K |
| Howard J Lee Yardley, PA | Pulmonary Disease | 19 | Under 11 | $169K |
| Ross M Hoffman Asheville, NC | Pulmonary Disease | 15 | Under 11 | $163K |
| Matthew E Woodske Beaver, PA | Pulmonary Disease | 20 | Under 11 | $162K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Genentech, Inc. ROG.SW | 4,228 | $42.1M |